Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-escalation study of OMS721 in thrombotic microangiopathy
2014-001032-11Phase 2Completed
- Sponsor
- Omeros Corporation
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of narsoplimab in thrombotic microangiopathies (TMA), sponsored by Omeros Corporation. Started Jun 2014; status: completed.
02
Drugs
narsoplimab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2014-001032-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001032-11.